冠心病患者替格瑞洛相关呼吸困难预测因素的分析

董加建; 宋爽; 马心超; 陈愿; 崔留义; 赵子明

doi:10.13201/j.issn.1001-1439.2018.10.012

冠心病患者替格瑞洛相关呼吸困难预测因素的分析

- 郑州市第七人民医院心内科(郑州, 450006)

详细信息

通讯作者: 董加建,E-mail:dongjiajian415@163.com

中图分类号: R541.4

收稿日期: 2018-03-22

修回日期: 2018-05-06

Analysis of the predictors of ticagrelor-associated dyspnea in patients with coronary heart disease

- Department of Cardiology, the Seventh People's Hospital of Zhengzhou, Zhengzhou, 450006, China

More Information

Corresponding author: DONG Jiajian, E-mail: dongjiajian415@163.com

Received Date: 22 March 2018

Revised Date: 06 May 2018

摘要

摘要: 目的:探讨冠心病 (CHD) 经皮冠状动脉介入治疗 (PCI) 患者在服用替格瑞洛期间发生呼吸困难的预测因素。方法:选择293例行PCI服用替格瑞洛的CHD患者, 58例 (19.8%) 发生替格瑞洛相关呼吸困难 (A组), 235例 (80.2%) 未发生替格瑞洛相关呼吸困难 (B组);2组在年龄、性别、吸烟、贫血方面, 差异有统计学意义 (P＜0.05);与未发生出血事件的患者相比, 发生出血事件的患者呼吸困难的发生率明显升高 (35.3%:16.5%, 单因素分析OR=1.973, P=0.035)。多因素logistic回归分析显示年龄、吸烟、贫血、出血事件与呼吸困难发生呈正相关。结果:结论:PCI治疗的CHD患者应用替格瑞洛出现替格瑞洛相关呼吸困难的风险较高, 年龄、吸烟、贫血、出血事件为发生呼吸困难的预测因素。
- 冠心病 /
- 替格瑞洛 /
- 呼吸困难
Abstract: Objective: To investigate the predictors of ticagrelor-related dyspnea in patients with coronary artery disease undergoing percutaneous coronary intervention.Method: Of 293 coronary heart disease (CHD) patients who taking ticagrelor and undergoing percutaneous coronary intervention (PCI), 58 cases (19.8%) showed ticagrelor-related dyspnea and remained 235 cases (80.2%) did not.Between the two groups, age, gender, smoking and anemia were significant different (P＜0.05).Compared with patients who had no bleeding events, patients with bleeding had significantly increased incidence of dyspnea (35.3%:16.5%, univariate analysis OR=1.973, P=0.035).Multivariate logistic regression analysis showed that age, smoking, anemia and bleeding events were positively correlated with dyspnea.Result: Conclusion: There is a high risk of ticagrelor-related dyspnea in patients with coronary artery disease treated with percutaneous coronary intervention.Age, smoking, anemia and bleeding events are predictors of dyspnea.
- coronary heart disease /
- ticagrelor /
- dyspnea

HTML全文

参考文献(13)

[1]	Am sterdam EA, Wenger NK, Brindis RG, et al.2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronarysyndromes:executive summary:a report of the American College of Cardiology/American HeartAssociation Task Force on Practice Guidelines[J].Circulation, 2014, 130 (25):2354-2394.
[2]	Roffi M, Patrono C, Collet JP, et al.2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation:Task Force for the Management of Acute CoronarySyndromes in Patients Presenting without Persistent ST-Segment Elevation of the EuropeanSociety of Cardiology (ESC)[J].Eur Heart J, 2016, 37 (3):267-315.
[3]	徐承义, 苏唏, 宋丹, 等.替格瑞洛用于冠状动脉慢性完全闭塞病变经皮冠状动脉介入治疗术后的有效性和安全性研究[J].中国介入心脏病学杂志, 2015, 23 (2):105-108.
[4]	余志华, 祝炜, 柯于鹤, 等.CYP2C19指导高危冠状动脉疾病PCI术后抗血小板药物选择研究[J].临床心血管病杂志, 2017, 33 (11):1045-1048.
[5]	Wallentin L, Becker RC, Budaj A, et al.Ticagrelor versus clopidogrel in patients with acute coronary syndromes[J].N Engl J Med, 2009, 361 (11):1045-1057.
[6]	Gurbel PA, Bliden KP, Butler K, et al.Randomized double-blind assessment of the ONSET and OFFSET of the antiptatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease:The ONSE/OFSET study[J].Circulation, 2009, 120 (25):2577-2585.
[7]	Storey RF, Becker RC, Harrington RA, et al.Pulmonary function in patients with acute coronary syndrome treated with ticagrelor or clopidogrel (from the Platelet Inhibition and Patient Outcomes[PLATO]pulmonary function sabstudy)[J].Am J Cardiol, 201l, 108 (11):1542-1546.
[8]	Belchikov YG, Koenig SJ, Dipasquale EM.Potential role of endogenous adenosine in tieagrelor-induced dyspnea[J].Pharmacotherapy, 2013, 33 (8):882-887.
[9]	Bonello L, Laine M, Kipson N, et al.Ticagrelor increases adenosine plasma concentration in patients with an acute coronary syndrome[J].J Am Cull Cardiol, 2014, 63 (9):872-877.
[10]	王小东, 周华, 张旭敏, 等.氨茶碱对冠心病患者使用替格瑞洛致呼吸困难的干预研究[J].临床心血管病杂志, 2017, 33 (5):427-430.
[11]	Cattaneo M, Schulz R, Nylander S.Adenosine-mediated effects of ticagrelor:evidence and potential clinical relevance[J].J Am Coll Cardiol, 2014, 63 (23):2503-2509.
[12]	Serebmany VL.Viewpoin:reversible nature of platelet binding causing transfusion-related acute lung injury (TRALI) syndrome may explain dyspnea after ticagrelor and elinogrel[J].Thromb Haemost, 2012, 108 (6):1024-1027.
[13]	Lindholm D, Storey RF, Christersson C, et al.Design and rationale of TROCADERO:atrial of caffeine to alleviate dyspnea related to ticagrelor[J].Am Heart J, 2015, 170 (3):465-470.